GlassScriptPhysician profile
Wendy M Moses
NPI 1487681730
$16,148.07
in general payments reported to CMS, 2019-2025
61 companies · $2,905 in 2025
The $2,905 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,237 · 2020: $1,705 · 2021: $2,175 · 2022: $1,834 · 2023: $2,544 · 2024: $2,749 · 2025: $2,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,123 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,122.93 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,439.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,549.26 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,207.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,044.35 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $949.58 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $886.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $721.31 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $705.06 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $567.25 | 2019-2023 | Steglatro, Belsomra, Pneumovax 23 |
| Takeda Pharmaceuticals U.S.A., INC. | $537.98 | 2019-2025 | Trintellix |
| Allergan, INC. | $522.87 | 2019-2022 | |
| Axsome Therapeutics, INC. | $513.82 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $503.81 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.39 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $276.49 | 2019-2021 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $225.90 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $221.83 | 2022 | |
| Phathom Pharmaceuticals, INC. | $199.35 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $184.25 | 2019-2024 | Livalo, Seglentis |
| Ironshore Pharmaceuticals INC. | $150.95 | 2019-2024 | Jornay Pm |
| Amarin Pharma, INC. | $148.03 | 2019-2021 | |
| Astellas Pharma US INC | $129.37 | 2023-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $124.67 | 2021 | |
| Corium, LLC | $120.54 | 2021-2024 | Azstarys |
| Sanofi-Aventis U.S. LLC | $115.44 | 2019-2021 | |
| Ucb, INC. | $114.98 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $109.74 | 2020-2021 | |
| Dexcom, INC. | $108.03 | 2024-2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $104.58 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $95.53 | 2024-2025 | Rexulti, Vyepti |
| Abbott Laboratories | $88.46 | 2021-2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $85.36 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $76.90 | 2023-2025 | Quviviq, Quviviq |
| Exact Sciences Corporation | $74.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $72.00 | 2021-2024 | Licart, Tirosint |
| Corcept Therapeutics | $66.22 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $59.73 | 2025 | Rexulti |
| Tris Pharma INC | $54.27 | 2021-2023 | Dyanavel Xr |
| Shire North American Group INC | $53.97 | 2019 | |
| Ardelyx, INC. | $53.41 | 2025 | Ibsrela |
| Avanir Pharmaceuticals, INC. | $49.22 | 2019 | |
| Collegium Pharmaceutical, INC. | $47.31 | 2025 | Jornay Pm |
| Upsher-Smith Laboratories LLC | $46.25 | 2020 | |
| Neos Therapeutics, LP | $45.21 | 2019 | |
| Recor Medical INC | $36.51 | 2025 | Paradise Ultrasound Renal Denervation System |
| Abiomed | $31.77 | 2025 | |
| Arbor Pharmaceuticals, INC. | $31.60 | 2022 | |
| Inogen, INC. | $27.45 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Horizon Therapeutics Plc | $25.90 | 2019-2023 | Krystexxa |
| Sumitomo Pharma America, INC. | $22.61 | 2024 | Gemtesa |
| Tonix Medicines, INC. | $22.25 | 2025 | Tonmya |
| Vanda Pharmaceuticals INC. | $20.83 | 2024 | Fanapt |
| Xeris Pharmaceuticals, INC. | $18.96 | 2024 | Keveyis |
| Itamar Medical INC | $18.42 | 2023 | Watchpatone |
| Harmony Biosciences LLC | $16.26 | 2023 | Wakix |
| Boston Scientific Corporation | $16.04 | 2024 | |
| Adlon Therapeutics L.P. | $15.78 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.51 | 2025 | Caplyta |
| Eisai INC. | $12.80 | 2021 | |
| Esperion Therapeutics, INC. | $12.40 | 2022 | |
| Alexion Pharmaceuticals, INC. | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.